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poor, medium and good prognosis group for the clinical 
cohort and trial cohort respectively, while (by definition) the 
training cohort had 25%, 50% and 25% distribution. This means 
the model was able to classify poor and medium prognosis 
patients in the clinical cohort but the good prognosis patient 
group was very small, as the clinical cohort population was 
older, had more advanced cancers, more nodal spread and 
more non-glottic cancers which are unfavorable for the 
survival prognosis. 
 
Figure 1: Kaplan Meier survival curves for the training, 
clinical and trial cohort respectively. 
Conclusions: The technical infrastructure and model is able 
to support the prognosis prediction of laryngeal carcinoma 
patients in clinical cohort which could be used in future to 
personalize treatment, improve treatment quality and 
evaluate these practice changes. The model does not work 
well for the biased patient population in the trial cohort.  
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Purpose/Objective: The aim of the studies was to assess the 
role of telomerase in immortality state of HNSCC cell lines. 
Malignant tumors of the head and neck region differs natural 
clinical outcome and prognosis depending on the histological 
diagnosis and location. Despite that the diagnostic and 
therapeutic problems are similar. The gold standard of 
therapy these tumors, with a view to maximal radicalization 
of treatment, is combined therapy involving the local 
(surgery, radiotherapy) and systemic treatment 
(chemotherapy). Recently, the great interest arouses 
individualization of cytostatics selection, as well as gene 
therapy application. One of the targets is telomerase as the 
enzymatic complex participating in immortality of cancer 
cells. 
Materials and Methods: Knock down of telomerase (TERT 
subunit) by lentiviral vectors encoding shRNA on cancer cell 
lines derivated from HNSCC tumors (head and neck cancers 
are squamous cell carcinoma) and KB cells was carried out. 
The level of silencing was performed by qPCR and 
immunofluorescence staining. The impact of drugs (cisplatin 
and decetaxel) and ionizing radiation on the induction of 
apoptosis, cell cycle, yH2AX and cell proliferation rate via 
immunofluorescence staining, cytometer analysis and qPCR 
was also estimated. The telomere length measurement using 
a method based on qPCR was assessed. 
Results: There was shown an influence of telomerase 
depletion on apoptosis, proliferation rate and yH2AX 
expression both in non-treated control cell lines as on cell 
population after chemoradiotherapy. Moreover, the influence 
of telomerase knock-down on increased chemo-and 
radioresistance in vitro was proved.  
Conclusions: Our results demonstrate increased chemo- and 
radiosensitivity in HNSCC cell lines after telomerase 
silencing. Telomerase is likely to play a pivotal role in 
chemo- and radioresistance of selected HNSCC cell lines, 
however further studies are needed.  
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Purpose/Objective: Lung cancer is the most frequent 
malignant neoplasm with extremely poor prognosis. In 
earliest stages of the disease clinical benefit of radical 
surgical excision is similar to stereotactic body radiotherapy 
(SBRT). The success of high-dose SBRT is certainly related to 
the X-rays-induced apoptosis. However other, not-well 
characterized mechanisms may also contribute. We 
hypothesize that high dose SBRT causes an increase in the 
expression of multipeptide tumor antigens, which further 
may lead to a stimulation of specific immune response. Those 
mechanisms are not fully understood therefore we have 
designed a prospective study to determine radiation-induced 
immune response changes. The protocol was approved by 
Local Ethical Committee.  
Objective: to assess the effect of high dose ionizing radiation 
on changes in the expression of T cell activation markers 
(CD25, CD28, CTLA-4, PD-1) , transcription factors associated 
with Th1, Th2, Th17 and regulatory T cell subpopulations of 
CD4(+) T cells (T-bet, GATA-3, ROR-γt and FoxP3, 
respectively) in patients treated with SBRT for T1/2N0 M0 
NSCLC. 
Materials and Methods: Study group consists of patients with 
newly diagnosed NSCLC stage T1/2N0M0 qualified for SBRT. 
Patients with comorbidities of significant impact on immune 
system are excluded. Peripheral blood samples are collected 
three times from patients: before the treatment (n = 44), 2 
weeks (n = 37) and 12 weeks (n = 21) after SRBT. Expression 
level of selected proteins on peripheral blood lymphocytes is 
measured by flow cytometry. 
Results: The study was started in November 2013. Since then 
44 consented patients were included. SBRT was planned and 
delivered according to the Department’s treatment 
standards. Analysis of blood samples has shown that SRBT 
significantly increases numbers of PD-1(+) and CTLA-4(+) 
